Dermata Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Equity Securities (Details Narrative)

Equity Securities (Details Narrative) - USD ($)									1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
Equity Securities (Details Narrative) - USD ($)	Mar. 31, 2025	Mar. 27, 2025	Jan. 31, 2025	Jan. 21, 2025	Sep. 17, 2024	Aug. 02, 2024	May 31, 2024	May 21, 2024	Sep. 30, 2024	Jul. 31, 2024	Jun. 30, 2024	Mar. 31, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Sep. 16, 2024	Aug. 01, 2024	May 17, 2024	Nov. 30, 2023	May 26, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net proceeds from exercise of warrants														$ 977	$ 168
Warrants to purchase common stock														1,238,949
Common stock issuable upon exercise of warrants														2,103,974
Offering expenses														$ 50,495
Warrants outstanding														1,238,949		506,822
Net proceeds from offering														$ 7,980,804	$ 6,955,611
Shares held in abeyance														182,000
Preferred stock, shares authorized														10,000,000		10,000,000
Preferred stock, par value														$ 0.0001		$ 0.0001
Preferred stock, shares issued														0		0
Preferred stock, shares outstanding														0		0
Share price per share														$ 5.02
Intrinsic value of warrants outstanding														$ 0
January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net cash proceeds				$ 2,200,000
Offering expenses				400,000
January 2025 PIPE [Member] \| Company Insiders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate purchase price			$ 1,550,000	$ 1,550,000
September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net cash proceeds					$ 3,100,000
Offering expenses					$ 400,000
Pre-Funded Warrants [Member] \| January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price				$ 0.01
Warrants to purchase common stock				7,246
Warrants outstanding														0
Pre-Funded Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price					$ 0.01
Warrants to purchase common stock					191,256
Warrants outstanding														0		90,500
PIPE Warrants [Member] \| January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price				$ 12.70
Warrants to purchase common stock				200,785
Common stock issuable upon exercise of warrants				200,785
PIPE Warrants [Member] \| January 2025 PIPE [Member] \| Company Insiders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock			122,047	122,047
PIPE Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price					$ 15.80
Series A Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock					191,256
Common stock issuable upon exercise of warrants					191,256
Series B Warrants [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock					191,256
Common stock issuable upon exercise of warrants					191,256
May 2024 Series A Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price														$ 49.10
Warrants outstanding														2,334		60,117
May 2024 Series B Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price														$ 49.10
Warrants outstanding																43,149
March 2025 Warrant Inducement Series A Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price														$ 12.84
Warrants outstanding														498,080
March 2025 Warrant Inducement Series B Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price														$ 12.84
Warrants outstanding														468,813
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares of common stock issued												60,200	55,001
Shares held in abeyance														182,000
Common Stock [Member] \| January 2025 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold				193,539
Common Stock [Member] \| January 2025 PIPE [Member] \| Company Insiders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold			122,047	122,047
Common Stock [Member] \| September 2024 PIPE [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold					191,256
Common Stock [Member] \| ATM Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold									19,421	35,580	1,157,761					55,001
Offering expenses										$ 513
Fixed commission rate on gross sales price of common stock											3.00%
Gross proceeds from offering									$ 504,894	$ 1,157,248
Increase in maximum aggregate offering amount of common stock issuable						$ 505,000
Maximum aggregate offering amount of common stock issuable						$ 1,662,761												$ 1,157,761
Net proceeds from offering																$ 1,500,000
Additional proceeds									$ 1,792,315
March 2025 Inducement Letter Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price																	$ 15.80		$ 49.10
Net proceeds from exercise of warrants		$ 5,700,000
Shares of common stock issued														301,447
Warrants, issued, held in abeyance														182,000
March 2025 Inducement Letter Agreement [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price	$ 12.84	$ 12.84										$ 12.84
Net proceeds from exercise of warrants	$ 5,700,000
Warrants to purchase common stock	483,447											483,447
Equity issuance costs	$ 4,900,000
March 2025 Inducement Letter Agreement [Member] \| New Series A Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock		498,080
March 2025 Inducement Letter Agreement [Member] \| New Series B Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock		468,813
March 2025 Inducement Letter Agreement [Member] \| March 2025 Warrant Inducement Series A Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock	498,080											498,080
March 2025 Inducement Letter Agreement [Member] \| March 2025 Warrant Inducement Series B Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price	$ 12.84											$ 12.84
Warrants to purchase common stock	468,813											468,813
March 2025 Inducement Letter Agreement [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock		483,447
May 2024 Inducement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares held in abeyance										26,700
May 2024 Inducement [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price							$ 51.60	$ 51.60												$ 97.67	$ 324.00
Net proceeds from exercise of warrants							$ 2,300,000	$ 2,300,000
Warrants to purchase common stock							51,632	51,632
Equity issuance costs							$ 1,500,000
May 2024 Inducement [Member] \| May 2024 Series A Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common stock							60,117	60,117
May 2024 Inducement [Member] \| May 2024 Series B Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price							$ 49.10
Warrants to purchase common stock							43,149	43,149